MDxHealth (NASDAQ:MDXH) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPS

MDxHealth (NASDAQ:MDXH) announced its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06), Zacks reports. The company had revenue of $24.29 million during the quarter, compared to analysts’ expectations of $22.62 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. MDxHealth updated its FY 2025 guidance to EPS.

MDxHealth Stock Up 6.7%

MDxHealth stock opened at $1.90 on Friday. The company has a market capitalization of $89.85 million, a P/E ratio of -1.25 and a beta of 1.32. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $3.50. The stock has a 50-day simple moving average of $1.60 and a 200-day simple moving average of $1.85.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.